missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Cell Culture Media, Supplements, and Reagents
  4. Cell Culture Media
  5. Classical and Basal Cell Culture Media
  6. Serum-Free Cell Culture Media
  7. 11615130

Lonza™ BioWhittaker™ X-VIVO™ 20 Hematopoietic Serum-Free Culture Media

For adoptive immunotherapy and cellular therapy research

Brand:  Lonza™ BE04-448Q

Product Code. 11615130

  • 313.61 € / 1 L

Please to purchase this item. Need a web account? Register with us today!

Explore more special offers
This item is not returnable. View return policy

Description

Description

  • Does not contain any lymphokines required for activation of human lymphocytes
  • Intended for in vitro procedures
  • Device Master Records (DMRs) for these products are held in an FDA Master File
  • Chemically defined media optimized for specific cell types
  • For further manufacturing or laboratory use

  • Developed and optimized to support the generation of LAK cells from monocyte-depleted PBL at high density

  • Limited by Federal (USA) law to investigational use
  • These products are for research use only
  • Not approved for human or veterinary use, for application to humans or animals, or for use in clinical or in vitro procedures

TRUSTED_SUSTAINABILITY
Specifications

Specifications

2° to 8°C
Stem Cell Serum Free Media (SFM)
Gentamicin, Phenol Red
1 L
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.